Showing 3611-3620 of 4164 results for "".
- Cloudbreak Pharma Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pingueculahttps://modernod.com/news/cloudbreak-pharma-announces-positive-phase-2-results-for-cbt-004-in-patients-with-vascularized-pinguecula/2482896/Cloudbreak Pharma announced positive topline results from its phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. The multicenter, randomized, double-maske
- Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lenshttps://modernod.com/news/ocumetics-initiates-first-in-human-study-of-accommodating-intraocular-lens/2482866/Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens. Designed to mimic the natural focusing ability of the youthful hu
- Heidelberg Engineering Launches ZinserLab Innovation Hub to Accelerate Imaging Innovation in Eye Carehttps://modernod.com/news/heidelberg-engineering-launches-zinserlab-innovation-hub-to-accelerate-imaging-innovation-in-eye-care/2482848/Heidelberg Engineering announced the launch of the ZinserLab, an innovation hub that aims to accelerate the development of imaging technologies with clinical value for eye care. The hub is named in honor of Dr. Gerhard Zinser, the
- Heidelberg Engineering Showcases Technologies to Enhance the Future of Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-showcases-technologies-to-enhance-the-future-of-imaging-technology-at-arvo/2482771/Heidelberg Engineering announced a portfolio of innovations aimed at redefining image quality, clinical research, and patient care in ophthalmology at ARVO. According to Heidelberg, Chameleon Imaging Research Platform is des
- Alcon Acquires Majority Interest in Aurion Biotechhttps://modernod.com/news/alcon-acquires-majority-interest-in-aurion-biotech-to-advance-cell-therapy-for-corneal-endothelial-disease/2482718/Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing cell therapies to treat eye diseases. Financial terms of the deal were not disclosed.
- Nicox Announces Data Collection Complete, NCX 470 Phase 3b Whistler Glaucoma Trialhttps://modernod.com/news/nicox-announces-data-collection-complete-ncx-470-phase-3b-whistler-glaucoma-trial/2482709/Nicox announced today that the last patient completed their final visit in the Whistler phase 3b clinical trial investigating the efficacy of NCX470 to lower IOP. This marks the end of their
- Aviceda Therapeutics Raises $207.5 Million to Advance Lead Program AVD-104 for Geographic Atrophy into Phase 3 Testinghttps://modernod.com/news/aviceda-therapeutics-raises-2075-million-to-advance-lead-program-avd-104-for-geographic-atrophy-into-phase-3-testing/2482603/Aviceda Therapeutics announced the closing of a $207.5 million Series C financing to propel the company’s pivotal phase 3 clinical trial for AVD-104, a treatment candidate for geographic atrophy
- Opus Genetics Receives FDA Agreement Under SPA for Phase 3 Trial of APX3330 in DRhttps://modernod.com/news/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy/2482587/Opus Genetics announced it has reached agreement with the FDA on a Special Protocol Assessment (SPA) for a phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf
- Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposiumhttps://modernod.com/news/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women-in-ophthalmology-wio-summer-symposium/2481795/Ocuphire Pharma announced that data from its phase 2 clinical trial of APX3330 in diabetic retinopathy (DR) were featured in an oral presentation on Saturday, August 26 at the